Literature DB >> 18308160

Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: the Rancho Bernardo Study.

Lori B Daniels1, Gail A Laughlin, Mark J Sarno, Ricki Bettencourt, Robert L Wolfert, Elizabeth Barrett-Connor.   

Abstract

OBJECTIVES: Lipoprotein-associated phospholipase A2 (Lp-PLA2) levels predict incident coronary heart disease (CHD) in adults without known CHD, independent of heart disease risk factors. We examined whether the independent association was apparent in older adults.
BACKGROUND: Serum levels of Lp-PLA2, an enzyme that hydrolyzes oxidized phospholipids to yield potentially proatherogenic particles, have been associated with CHD and may help predict cardiovascular risk.
METHODS: Participants were 1,077 community-dwelling men and women, median age 72 years, who had no known CHD at baseline (1984 to 1987) when blood samples and risk factor data were collected. Participants were followed for CHD events for a mean of 16 years, through 2002. Cox proportional hazards regression models were used to examine the association of serum Lp-PLA2 with incident CHD (myocardial infarction, angina, or coronary revascularization).
RESULTS: The Lp-PLA2 levels positively correlated with age (r = 0.09), body mass index (r = 0.11), low-density lipoprotein (r = 0.37), triglycerides (r = 0.25), and C-reactive protein (r = 0.10), and negatively correlated with high-density lipoprotein (r = -0.27) (all p < 0.05). During follow-up, 228 participants had incident CHD events. Lipoprotein-associated phospholipase A2 levels in the second, third, and fourth quartiles predicted an increased risk of CHD compared with the lowest quartile (hazard ratios 1.66, 1.80, and 1.89, respectively; p < 0.05 for each). This association persisted after adjusting for C-reactive protein and other CHD risk factors.
CONCLUSIONS: Elevated Lp-PLA2 levels predict CHD events in apparently healthy older adults, independent of CHD risk factors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18308160      PMCID: PMC3096479          DOI: 10.1016/j.jacc.2007.10.048

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  17 in total

1.  The diagnosis of ischaemic heart pain and intermittent claudication in field surveys.

Authors:  G A ROSE
Journal:  Bull World Health Organ       Date:  1962       Impact factor: 9.408

2.  Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions.

Authors:  T Häkkinen; J S Luoma; M O Hiltunen; C H Macphee; K J Milliner; L Patel; S Q Rice; D G Tew; K Karkola; S Ylä-Herttuala
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-12       Impact factor: 8.311

3.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach.

Authors:  E R DeLong; D M DeLong; D L Clarke-Pearson
Journal:  Biometrics       Date:  1988-09       Impact factor: 2.571

4.  Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis.

Authors:  Frank D Kolodgie; Allen P Burke; Kristi S Skorija; Elena Ladich; Robert Kutys; Addisalem Taye Makuria; Renu Virmani
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-09-07       Impact factor: 8.311

5.  Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Christie M Ballantyne; Ron C Hoogeveen; Heejung Bang; Josef Coresh; Aaron R Folsom; Lloyd E Chambless; Merle Myerson; Kenneth K Wu; A Richey Sharrett; Eric Boerwinkle
Journal:  Arch Intern Med       Date:  2005-11-28

6.  Association of lipoprotein-associated phospholipase A2 mass and activity with calcified coronary plaque in young adults: the CARDIA study.

Authors:  Carlos Iribarren; Myron D Gross; Jeanne A Darbinian; David R Jacobs; Stephen Sidney; Catherine M Loria
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-10-21       Impact factor: 8.311

7.  Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group.

Authors:  C J Packard; D S O'Reilly; M J Caslake; A D McMahon; I Ford; J Cooney; C H Macphee; K E Suckling; M Krishna; F E Wilkinson; A Rumley; G D Lowe
Journal:  N Engl J Med       Date:  2000-10-19       Impact factor: 91.245

8.  Lipoprotein-associated phospholipase A2 is an independent marker for coronary endothelial dysfunction in humans.

Authors:  Eric H Yang; Joseph P McConnell; Ryan J Lennon; Gregory W Barsness; Geralyn Pumper; Stacy J Hartman; Charanjit S Rihal; Lilach O Lerman; Amir Lerman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-10-20       Impact factor: 8.311

9.  Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study.

Authors:  Hok-Hay S Oei; Irene M van der Meer; Albert Hofman; Peter J Koudstaal; Theo Stijnen; Monique M B Breteler; Jacqueline C M Witteman
Journal:  Circulation       Date:  2005-02-08       Impact factor: 29.690

10.  Prevalence of small vessel and large vessel disease in diabetic patients from 14 centres. The World Health Organisation Multinational Study of Vascular Disease in Diabetics. Diabetes Drafting Group.

Authors: 
Journal:  Diabetologia       Date:  1985-09       Impact factor: 10.122

View more
  33 in total

Review 1.  Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2.

Authors:  Robert S Rosenson; Diana M Stafforini
Journal:  J Lipid Res       Date:  2012-06-04       Impact factor: 5.922

2.  Implication of lipoprotein associated phospholipase A2 activity in oxLDL uptake by macrophages.

Authors:  Konstantinos P Markakis; Maria K Koropouli; Stavroula Grammenou-Savvoglou; Ewoud C van Winden; Andromaxi A Dimitriou; Constantinos A Demopoulos; Alexandros D Tselepis; Eleni E Kotsifaki
Journal:  J Lipid Res       Date:  2010-03-23       Impact factor: 5.922

3.  Lipoprotein-associated phospholipase A2 and risk of incident cardiovascular disease in a multi-ethnic cohort: The multi ethnic study of atherosclerosis.

Authors:  Parveen K Garg; Robyn L McClelland; Nancy S Jenny; Michael H Criqui; Philip Greenland; Robert S Rosenson; David S Siscovick; Neal Jorgensen; Mary Cushman
Journal:  Atherosclerosis       Date:  2015-05-16       Impact factor: 5.162

4.  Lipoprotein phospholipase A2 in patients with isolated coronary artery ectasia.

Authors:  Levent Korkmaz; Emre Erkuş; Abdulkadir Kırış; Mustafa Tarık Ağaç; Zeydin Acar; Turhan Turan; Hakan Erkan; Ihsan Dursun; Sükrü Celik
Journal:  Clin Res Cardiol       Date:  2011-01-05       Impact factor: 5.460

5.  Translational studies of lipoprotein-associated phospholipase A₂ in inflammation and atherosclerosis.

Authors:  Jane F Ferguson; Christine C Hinkle; Nehal N Mehta; Roshanak Bagheri; Stephanie L Derohannessian; Rhia Shah; Megan I Mucksavage; Jonathan P Bradfield; Hakon Hakonarson; Xuexia Wang; Stephen R Master; Daniel J Rader; Mingyao Li; Muredach P Reilly
Journal:  J Am Coll Cardiol       Date:  2012-02-21       Impact factor: 24.094

Review 6.  Proteomics Research in Cardiovascular Medicine and Biomarker Discovery.

Authors:  Maggie P Y Lam; Peipei Ping; Elizabeth Murphy
Journal:  J Am Coll Cardiol       Date:  2016-12-27       Impact factor: 24.094

7.  An effect of moderate hepatic impairment on the pharmacokinetics and safety of darapladib.

Authors:  Mindy He Magee; Shawn Shearn; Bonnie Shaddinger; Zixing Fang; Ruchira Glaser
Journal:  Br J Clin Pharmacol       Date:  2014-11       Impact factor: 4.335

8.  Associations of platelet-activating factor acetylhydrolase (PAF-AH) gene polymorphisms with circulating PAF-AH levels and risk of coronary heart disease or blood stasis syndrome in the Chinese Han population.

Authors:  Guo-Hua Zheng; Shang-Quan Xiong; Hai-Ying Chen; Li-Juan Mei; Ting Wang
Journal:  Mol Biol Rep       Date:  2014-07-18       Impact factor: 2.316

9.  Systematic Review of the Association between Lipoprotein-Associated Phospholipase A2 and Atherosclerosis.

Authors:  Jing Liu; Yuling Hong; Yue Qi; Fan Zhao; Dong Zhao
Journal:  N Am J Med Sci (Boston)       Date:  2011-10

10.  Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity, platelet-activating factor acetylhydrolase (PAF-AH) in leukocytes and body composition in healthy adults.

Authors:  Paraskevi Detopoulou; Tzortzis Nomikos; Elizabeth Fragopoulou; Demosthenis B Panagiotakos; Christos Pitsavos; Christodoulos Stefanadis; Smaragdi Antonopoulou
Journal:  Lipids Health Dis       Date:  2009-06-05       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.